Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00742209 · ClinicalTrials.gov registry record · Phase 2
Prevention Study in Adult Patients Suffering From Migraine Headaches
A Phase 2 study of Migraine and Migraine Disorders, sponsored by XenoPort.
- Completed
- Registry status
- Phase 2
- Development phase
- 526
- Enrollment target
- 20
- Study locations
NCT00742209: Completed Phase 2 study of Migraine and Migraine Disorders, sponsored by XenoPort.
NCT00742209 is a Phase 2 study of Migraine and Migraine Disorders that has completed, run by XenoPort. The registered enrollment target is 526 participants, above the 353-participant average among 102 other Migraine trials with a reported enrollment target (49% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00742209, a Phase 2 study of Migraine and Migraine Disorders, has completed, sponsored by XenoPort.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 526 participants
- Enrollment target
- 20
- Study locations
Study Summary
Purpose of the study is to evaluate dose response relationship, efficacy, safety and tolerability of target doses of GSK1838262 compared to placebo in the prophylactic treatment of migraine headache. Once subjects complete the baseline and meet the randomization criteria, they will complete a 5-wk flexible titration period and then enter the 12 week maintenance period.
Primary Outcome
A migraine headache day is defined as a calendar day with any occurrence of migraine headache pain of at least 30 minutes in duration. Change from baseline was calculated as the mean number of MHD over the last 4 weeks of treatment prior to taper minus the number at baseline using the Last Observation Carried Forward (LOCF). The last 4-week treatment phase is based on the last 4 weeks prior to taper for each participant.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GSK1838262
Study Locations (20)
California
- GSK Investigational Site - Anaheim
- GSK Investigational Site - Newport Beach
- GSK Investigational Site - Redlands
- GSK Investigational Site - San Francisco
- GSK Investigational Site - Santa Monica
- GSK Investigational Site - Westlake Village
Colorado
- GSK Investigational Site - Colorado Springs
- GSK Investigational Site - Colorado Springs
- GSK Investigational Site - Denver
Florida
- GSK Investigational Site - DeLand
- GSK Investigational Site - Sunrise
- GSK Investigational Site - West Palm Beach
Arizona
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Phoenix
Georgia
- GSK Investigational Site - Atlanta
- GSK Investigational Site - Stockbridge
Alabama
- GSK Investigational Site - Birmingham
Illinois
- GSK Investigational Site - Chicago
Kansas
- GSK Investigational Site - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 526 participants |
| Start Date | 2008-08 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
What the finished NCT00742209 record still lists
NCT00742209 is an interventional study that assigns participants to a tested intervention. The registered 526 participants enrollment target is mid-sized for trials with a published cap, above the 353-participant average among 102 other Migraine trials with a reported enrollment target (49% higher).
The record links to 2 conditions, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00742209 names 20 study sites across 9 states, led by California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT00742209 about?
NCT00742209 is a clinical study titled "Prevention Study in Adult Patients Suffering From Migraine Headaches". Purpose of the study is to evaluate dose response relationship, efficacy, safety and tolerability of target doses of GSK1838262 compared to placebo in the prophylactic treatment of migraine headache. Once subjects complete the baseline and meet the randomization criteria, they will complete a 5-wk f...
What is the current status of trial NCT00742209?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 526 participants. The study started on 2008-08. Estimated completion is 2010-06.
What conditions does trial NCT00742209 study?
This clinical trial studies the following conditions: Migraine, Migraine Disorders.
What interventions are being tested in trial NCT00742209?
The interventions under investigation include: Placebo (DRUG), GSK1838262 (DRUG).
Who is sponsoring clinical trial NCT00742209?
This trial is sponsored by XenoPort, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00742209 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00742209's enrollment target sits among peer trials
526 21st of 102 higher than 82 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Migraine Manager (R01)
RECRUITING · Phase 2
-
Bilateral Middle Meningeal Artery Lidocaine Infusion for Chronic Debilitating Migraines
RECRUITING · Phase 2
-
Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
RECRUITING · Phase 2
-
A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04738825 · 526 participants · NA
Promoting HIV Risk Reduction Among People Who Inject Drugs: A Stepped Care Approach Using Contingency Management With PrEP Adherence and Support Services
- NCT04769492 · 525 participants · NA
#ChopViolence/#ChopHIV
- NCT05260047 · 525 participants · NA
Culturally Responsive Community Driven Substance Use Recovery for Black and Latinx Population
- NCT05620719 · 525 participants · NA
Multisite Advancement of Research on Chronic Posttraumatic Headache
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia